Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial

Pignon, 2009, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, 92, 4, 10.1016/j.radonc.2009.04.014 Budach, 2005, J Clin Oncol, 23, 1125, 10.1200/JCO.2005.07.010 Nordsmark, 1996, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, Radiother Oncol, 41, 31, 10.1016/S0167-8140(96)91811-3 Horsman, 2012, Imaging hypoxia to improve radiotherapy outcome, Nat Rev Clin Oncol, 9, 674, 10.1038/nrclinonc.2012.171 Zips, 2012, Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer, Radiother Oncol, 105, 21, 10.1016/j.radonc.2012.08.019 Mortensen, 2012, FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial, Radiother Oncol, 105, 14, 10.1016/j.radonc.2012.09.015 Zegers, 2016, Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer, Eur J Nucl Med Mol Imaging, 43, 2139, 10.1007/s00259-016-3429-y Servagi-Vernat, 2014, A prospective clinical study of (1)(8)F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy, Eur J Nucl Med Mol Imaging, 41, 1544, 10.1007/s00259-014-2730-x Toustrup, 2011, Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer, Cancer Res, 71, 5923, 10.1158/0008-5472.CAN-11-1182 Hicks, 2005, Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent, Eur J Nucl Med Mol Imaging, 32, 1384, 10.1007/s00259-005-1880-2 Eustace, 2013, A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer, Clin Cancer Res, 19, 4879, 10.1158/1078-0432.CCR-13-0542 Janssens, 2012, Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial, J Clin Oncol, 30, 1777, 10.1200/JCO.2011.35.9315 Lee, 2016, Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma, Int J Radiat Oncol Biol Phys, 96, 9, 10.1016/j.ijrobp.2016.04.027 Linge, 2016, Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(−) HNSCC after postoperative radiochemotherapy: a Multicenter Study of the DKTK-ROG, Clin Cancer Res, 22, 2639, 10.1158/1078-0432.CCR-15-1990 Tawk, 2016, Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma, Radiother Oncol, 118, 350, 10.1016/j.radonc.2015.11.027 Zegers, 2014, In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging, Clin Cancer Res, 20, 6389, 10.1158/1078-0432.CCR-14-1524 Thorwarth, 2007, Hypoxia dose painting by numbers: a planning study, Int J Radiat Oncol Biol Phys, 68, 291, 10.1016/j.ijrobp.2006.11.061 Dirix, 2009, Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI, J Nucl Med., 50, 1020, 10.2967/jnumed.109.062638 Bittner, 2013, Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy, Radiother Oncol, 108, 511, 10.1016/j.radonc.2013.06.012 Wiedenmann, 2015, Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome, Radiother Oncol, 117, 113, 10.1016/j.radonc.2015.09.015 Okamoto, 2016, The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy, Eur J Nucl Med Mol Imaging, 43, 2147, 10.1007/s00259-016-3431-4 Bruine de Bruin, 2015, Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry, Radiother Oncol, 117, 106, 10.1016/j.radonc.2015.07.012 Bollineni, 2014, Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies, Radiother Oncol, 113, 198, 10.1016/j.radonc.2014.10.010 van Elmpt, 2016, Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion, Eur J Nucl Med Mol Imaging, 43, 240, 10.1007/s00259-015-3169-4 Peeters, 2015, TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging, Clin Cancer Res, 21, 2984, 10.1158/1078-0432.CCR-15-0018 Halle, 2012, Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI, Cancer Res, 72, 5285, 10.1158/0008-5472.CAN-12-1085 Lambrecht, 2014, Integrating pretreatment diffusion weighted MRI into a multivariable prognostic model for head and neck squamous cell carcinoma, Radiother Oncol, 110, 429, 10.1016/j.radonc.2014.01.004 Schutze, 2014, Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice, Radiother Oncol, 111, 81, 10.1016/j.radonc.2014.02.005 Dubois, 2015, New ways to image and target tumour hypoxia and its molecular responses, Radiother Oncol, 116, 352, 10.1016/j.radonc.2015.08.022 Thorwarth, 2005, A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia, Phys Med Biol, 50, 2209, 10.1088/0031-9155/50/10/002 Thorwarth, 2007, A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations, Int J Radiat Oncol Biol Phys, 68, 515, 10.1016/j.ijrobp.2006.12.037 Thorwarth, 2005, Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer, BMC Cancer, 5, 152, 10.1186/1471-2407-5-152 Gregoire, 2003, CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines, Radiother Oncol, 69, 227, 10.1016/j.radonc.2003.09.011 Servagi-Vernat, 2015, Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study, Acta Oncol, 54, 1008, 10.3109/0284186X.2014.990109 Muzi, 2015, 18F-fluoromisonidazole quantification of hypoxia in human cancer patients using image-derived blood surrogate tissue reference regions, J Nucl Med, 56, 1223, 10.2967/jnumed.115.158717 Wang, 2010, Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer, J Nucl Med, 51, 37, 10.2967/jnumed.109.067009 Monnich, 2015, Robustness of quantitative hypoxia PET image analysis for predicting local tumor control, Acta Oncol, 54, 1364, 10.3109/0284186X.2015.1071496 Yaromina, 2011, Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts, Int J Radiat Oncol Biol Phys, 80, 1205, 10.1016/j.ijrobp.2011.02.015 Zschaeck, 2015, Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure, Acta Oncol, 54, 1355, 10.3109/0284186X.2015.1074720 Jentsch, 2016, Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours, Radiother Oncol, 10.1016/j.radonc.2016.07.024 Even, 2015, PET-based dose painting in non-small cell lung cancer: comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes, Radiother Oncol, 116, 281, 10.1016/j.radonc.2015.07.013 Rasmussen, 2016, Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer, Radiother Oncol, 120, 76, 10.1016/j.radonc.2016.03.005 Lassen, 2014, Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer, Radiother Oncol, 113, 310, 10.1016/j.radonc.2014.11.032 Duprez, 2011, Adaptive dose painting by numbers for head-and-neck cancer, Int J Radiat Oncol Biol Phys, 80, 1045, 10.1016/j.ijrobp.2010.03.028 Madani, 2011, Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer, Radiother Oncol, 101, 351, 10.1016/j.radonc.2011.06.020 Wang, 2015, A randomized pilot trial comparing position emission tomography (PET)-guided dose escalation radiotherapy to conventional radiotherapy in chemoradiotherapy treatment of locally advanced nasopharyngeal carcinoma, PLoS ONE, 10 Leclerc, 2013, A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach, Radiother Oncol, 106, 333, 10.1016/j.radonc.2013.03.002